Gastrointestinal Endoscopy Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The gastrointestinal endoscopy devices market size is projected to be USD 20.85 billion in 2025, USD 22.24 billion in 2026, and reach USD 30.70 billion by 2031, growing at a CAGR of 6.66% from 2026 to 2031. This report is Segmented by Product Type (Endoscopes, Visualization Equipment, Operative Devices), Reusability (Reusable, Single-Use), Age Group (Adults, Geriatrics, Pediatrics), Application (Diagnostics, Therapeutics), End User (Hospitals, Ambulatory Surgery Centers, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Gastrointestinal Endoscopy Devices Market Trends and Insights

Rising Colorectal And Gastric Cancer Screening Demand

The gastrointestinal endoscopy devices market continues to draw its core volume from colorectal and upper gastrointestinal cancer screening, and that demand base remains durable in 2026. The American Cancer Society estimates 158,850 new colorectal cancer cases in the United States in 2026, and one-third of the expected 55,230 deaths is projected to occur in patients younger than 65, which is pushing payers and health systems to broaden screening access across more age groups. A second demand layer comes from younger adults, because 22% of colorectal cancer cases in 2022 were diagnosed in people younger than 55, up from 11% in 1995, which increases lifetime screening and surveillance needs for a larger patient pool. Screening uptake is also moving in the right direction, as the U.S. rate rose from 59% in 2021 to 65% in 2023 among adults aged 45 and older, and total patients screened at health centers reached 3,617,246 in 2024. Positive results from noninvasive tests still drive patients into colonoscopy, so newer screening formats are not removing procedures from the gastrointestinal endoscopy devices market, but are instead adding a wider referral funnel into it. Fujifilm’s 2026 investor material also supports that longer demand picture, as it expects the global gastrointestinal endoscopy field to sustain 4% to 6% annual growth on the back of aging populations and rising cancer incidence in both mature and developing markets.

Rapid Shift Toward Single-Use Endoscopy For Infection Control

The gastrointestinal endoscopy devices market is also being lifted by the wider shift toward single-use devices for infection control. The original case for disposable endoscopes began with duodenoscopes, but the same purchasing logic is now moving into bronchoscopy and selected gastrointestinal procedures where contamination risk carries greater clinical and legal weight. Evidence published in 2025 showed that high-level disinfection does not reliably eliminate microorganisms in real-world practice, with high-concern organisms and multidrug-resistant organisms still found on reprocessed devices. That evidence is shaping policy discussions and technology review work, including the AHRQ review of disposable endoscope use that was updated in September 2025. Another practical driver is training consistency in teaching hospitals, because single-use devices remove wear-related variation from one procedure to the next and reduce uncertainty linked to reprocessing quality. As more manufacturers widen indications and product lines, the gastrointestinal endoscopy devices market is likely to see durable demand for disposable systems in settings where safety assurance matters more than reuse economics.

High Capital Cost Of Capital Equipment And Imaging Towers

The gastrointestinal endoscopy devices market still faces a clear ceiling from the cost of premium imaging systems, processors, AI modules, and full tower setups. New platforms are adding clinical value, but they also raise acquisition cost at a time when many community hospitals and public systems remain careful with capital budgets. Fujifilm’s ELUXEO 8000 reflects that direction, with 4K imaging, triple noise reduction, and Amber-Red Color Imaging aimed at more advanced procedures, yet the price of system-level adoption can limit uptake outside higher-volume facilities. Replacement timing adds another constraint because many hospitals refresh imaging equipment on a 7 to 10 year cycle, which is slower than the current push toward AI-ready platforms. The problem is more pronounced in emerging markets, where weaker service support and tighter procurement budgets can shift demand toward lower-cost local systems or modular components instead of full integrated platforms. This keeps part of the gastrointestinal endoscopy devices market tied to slower conversion cycles even when clinical demand remains healthy.

Other drivers and restraints analyzed in the detailed report include:

• AI-Assisted Lesion Detection And Documentation
• Expansion Of Ambulatory And Outpatient GI Procedure Capacity
• Reprocessing Burden And Infection-Control Compliance Costs

Segment Analysis

Endoscopes held the largest product type share at 38.31% in 2025, reflecting the central role of flexible colonoscopes and gastroscopes across diagnostic and therapeutic gastrointestinal workflows. Their scale is supported by routine use in screening, surveillance, and intervention, which gives them a broader demand base than any other product group in the gastrointestinal endoscopy devices market. Flexible products remain dominant inside this category, while disposable formats are expanding faster within specific infection-sensitive settings. Operative devices and accessories continue to provide recurring sales, because biopsy forceps, snares, clips, and electrosurgical tools are used across a large installed base and are less exposed to hospital capital delays.

Visualization equipment is projected to record the highest CAGR at 8.38% through 2031, which shows that the current upgrade cycle is increasingly tied to processors, monitors, towers, and software-ready platforms rather than only to scopes. Olympus supported that cycle when it received FDA 510(k) clearance in May 2025 for the EZ1500 series with Extended Depth of Field technology, which improved image sharpness at closer distances and created a practical reason to refresh compatible installed systems. Fujifilm’s ELUXEO 8000 further reinforced the same pattern in 2026 with 4K imaging and Amber-Red Color Imaging aimed at more complex endoscopy work. The commercial appeal is stronger because imaging processors are now increasingly paired with annual AI software licenses, which raises total contract value and keeps customers inside one vendor ecosystem for a longer period.

Reusable endoscopes commanded 80.24% of revenue in 2025, supported by the deep installed base in hospital gastrointestinal labs and the lower cost per procedure that high-volume centers can still achieve with reuse. That installed base remains important because clinicians are familiar with reusable handling, hospitals already own the supporting infrastructure, and many advanced procedures still depend on reusable systems. Even so, the gastrointestinal endoscopy devices market is seeing faster growth in single-use formats where contamination risk is less acceptable or patient profiles are more sensitive. Adoption is strongest in procedures and settings where a reprocessing failure would create disproportionate clinical, financial, or legal exposure.

Single-use endoscopes are projected to grow at a 7.52% CAGR through 2031, and that pace reflects a broader move from narrow rescue use into more regular procurement planning. A 2024 Delphi consensus on disposable endoscopy linked current adoption most clearly to patients with multidrug-resistant organism exposure and noted that broader use will depend on more cost-effectiveness and clinical evidence, which suggests a steady but still selective expansion path. The competitive issue is not limited to disposable versus reusable, because hybrid formats with reusable bodies and single-use distal mechanisms could become an attractive option in medium-volume sites. Micro-Tech also showed continued momentum in disposable and endotherapy-linked innovation with multiple FDA 510(k) clearances through April 2026, which points to a wider accessory and intervention ecosystem developing around less reuse-intensive workflows. As manufacturing scale improves and more procedure types become eligible, the gastrointestinal endoscopy devices market is likely to keep shifting part of infection-control spending away from reprocessing infrastructure and toward device replacement.

Complete Report Scope:

• By Product Type
  • Endoscopes
    • Flexible Endoscopes
    • Rigid Endoscopes
    • Disposable Endoscopes
  • Visualization Equipment
  • Operative Devices and Accessories
• By Reusability
  • Reusable Endoscopes
  • Single-Use Endoscopes
• By Age Group
  • Adults
  • Geriatrics
  • Pediatrics
• By Application
  • Diagnostics
  • Therapeutics
• By End User
  • Hospitals
  • Ambulatory Surgery Centers
  • Specialty Clinics
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.22% of the gastrointestinal endoscopy devices market size in 2025, making it the largest regional contributor by revenue. The region benefits from high screening colonoscopy uptake, a mature ambulatory surgery center network, and payer support that increasingly favors preventive gastrointestinal procedures. The United States remains the main national driver because CMS expanded colorectal screening coverage from January 2025 to include CT colonography, blood-based biomarker tests, and Cologuard Plus, which widened the front end of the procedure funnel and preserved follow-on colonoscopy demand after positive results. Canada adds steadier public-system demand as provinces continue to address wait times and capacity needs, while Mexico is benefiting from private healthcare investment in urban markets. The gastrointestinal endoscopy devices market in North America is also being reshaped by physician-led ASC development in states such as Texas, Florida, and Arizona, which is shortening the shift from hospitals to outpatient care and creating a nearer-term replacement opportunity for mid-tier imaging systems.

Europe remains an important source of premium device demand, with Germany, France, and the United Kingdom supporting adoption of next-generation imaging and AI-linked platforms. EU MDR 2017/745 has lengthened market entry requirements for smaller suppliers, but it has also strengthened the position of larger companies that can support broader clinical evidence and post-market surveillance obligations. Italy and Spain are moving ahead with colorectal cancer screening modernization, which should support both colonoscopy volume and demand for single-use accessories over time. Central and Eastern Europe still offer room for penetration as public procurement cycles and healthcare infrastructure investment improve across parts of the region.

Asia-Pacific is projected to grow at an 8.65% CAGR through 2031, which makes it the fastest-growing regional segment in the gastrointestinal endoscopy devices market. Growth is being supported by broader screening efforts in China, India, and South Korea, alongside demand for both premium and value-tier systems as capacity expands across different hospital tiers. Japan remains a structurally important market because aging demographics and the wider use of ESD for early gastric cancer continue to support gastrointestinal endoscopy demand. Middle East and Africa and South America remain smaller, but they are moving along a similar path with a lag as health system modernization and public-private endoscopy expansion gradually improve procedure access.

List of Companies Covered in this Report:

• Ambu
• Beckton Dickinson
• Boston Scientific
• Conmed
• Cook Group
• Erbe Elektromedizin
• FUJIFILM
• Johnson & Johnson
• Karl Storz
• Medtronic
• MICRO-TECH (Nanjing) Co., Ltd.
• Olympus
• PENTAX Medical America, Inc.
• Richard Wolf
• Smart Medical Systems Ltd.
• Stryker
• Teleflex

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support